Analysts at StockNews.com assumed coverage on shares of Curis (NASDAQ:CRIS – Get Free Report) in a report issued on Thursday. The firm set a “hold” rating on the biotechnology company’s stock.
Separately, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Curis in a research report on Tuesday, December 10th.
Read Our Latest Analysis on CRIS
Curis Price Performance
Institutional Trading of Curis
Several hedge funds have recently bought and sold shares of CRIS. Focused Wealth Management Inc grew its position in Curis by 9.5% in the 4th quarter. Focused Wealth Management Inc now owns 59,204 shares of the biotechnology company’s stock worth $181,000 after purchasing an additional 5,138 shares during the last quarter. CM Management LLC boosted its position in shares of Curis by 83.3% during the fourth quarter. CM Management LLC now owns 220,000 shares of the biotechnology company’s stock worth $673,000 after buying an additional 100,000 shares during the period. Geode Capital Management LLC grew its holdings in Curis by 27.3% in the 4th quarter. Geode Capital Management LLC now owns 83,129 shares of the biotechnology company’s stock worth $254,000 after buying an additional 17,820 shares in the last quarter. M28 Capital Management LP increased its position in Curis by 23.5% in the 4th quarter. M28 Capital Management LP now owns 521,059 shares of the biotechnology company’s stock valued at $1,594,000 after acquiring an additional 99,108 shares during the period. Finally, Samsara BioCapital LLC acquired a new stake in Curis in the 4th quarter valued at approximately $607,000. 29.97% of the stock is currently owned by institutional investors.
About Curis
Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
Read More
- Five stocks we like better than Curis
- Where Do I Find 52-Week Highs and Lows?
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Pros And Cons Of Monthly Dividend Stocks
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Using the MarketBeat Dividend Tax Calculator
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.